Center of Excellence in Molecular Biology (CEMB), 87-West Canal Bank Road Thokar Niaz Baig, University of the Punjab, Lahore, Pakistan.
Faculty of Mathematics and Natural Sciences (FMIPA), Department of Microbiology, Institute Pertanian Bogor (IPB) University Bogor, Indonesia.
Crit Rev Eukaryot Gene Expr. 2021;31(3):21-34. doi: 10.1615/CritRevEukaryotGeneExpr.2021038075.
Coronaviruses (CoVs) are continuously emerging, highly transmissible, and pathogenic agents that primarily target the human respiratory system. Previous outbreaks of severe acute respiratory syndrome-CoV and Middle East respiratory syndrome-CoV remain life-threatening and global public health concerns. A novel CoV outbreak that occurred in December 2019 in Wuhan, China was declared a pandemic outbreak that has since killed millions of individuals worldwide. Rapid transmission, genetic variations, and unavailability of specific therapeutic drugs are major factors that led to this alarming and deadly situation. Currently, > 200 clinical vaccine trials are underway to combat infection. This review summarizes reports related to CoV origin, genetic variations, drug options, status of nine vaccines that were in phase III trials, and novel therapies including convalescent plasma and stem cell treatment.
冠状病毒(CoV)是不断出现的、高度传染性的、致病性病原体,主要针对人类呼吸系统。以前的严重急性呼吸综合征冠状病毒和中东呼吸综合征冠状病毒爆发仍然是危及生命的和全球公共卫生关注的问题。2019 年 12 月在中国武汉发生的一种新型 CoV 爆发被宣布为大流行爆发,此后已在全球造成数百万人死亡。快速传播、遗传变异和缺乏特定的治疗药物是导致这种令人震惊和致命情况的主要因素。目前,正在进行超过 200 项临床疫苗试验以对抗感染。本综述总结了有关 CoV 起源、遗传变异、药物选择、处于 III 期试验的九种疫苗的现状以及包括恢复期血浆和干细胞治疗在内的新型疗法的报告。